1. Medtech Insight
  2. >>Policy & Regulation

CMS Coverage-With-Evidence-Development Policy Could Face Revamp

CMS is taking comments through Jan. 6 on implementation of CED policies as part of national coverage determinations, how CED impacts Medicare beneficiaries and how new approaches might maximize benefits.

CMS last week signaled plans to revisit an underused tool for gathering clinical evidence on medical technologies with the opening of a public comment period on coverage with evidence development.

Under coverage with evidence, or CED, CMS provides reimbursement for services on the condition that additional data is collected via...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Policy & Regulation

Outdated SME Thresholds Need EU Review, Say German Medtechs

 
• By Ashley Yeo

Berlin medtech associations add to European voice requesting that the EU eases MDR/IVDR and other compliance costs on SMEs.

NextGen Dx Panel Expects Continued Limbo On LDT Regulation

 
• By Elizabeth Orr

A recent conference panel discussed the stagnation in diagnostics regulation, highlighting the FDA's failed regulatory efforts on lab-developed tests. Political and legislative challenges hinder other reforms, and concerns over Medicare reimbursement cuts loom for the clinical lab industry.

FDA’s New AI Councils Focus On ‘Responsible’ Adoption And Regulation

 
• By Sarah Karlin-Smith

The agency is creating two new AI councils to facilitate its role in responsible AI adoption and regulation.

Medtech Must Address AI Risks Now Or Jeopardize Its Future Potential, Expert Warns

 
• By Amanda Maxwell

Urgent action is needed to address gaps in how risks from medical devices and diagnostics utilizing AI are identified, mitigated and managed. So says James Pink, renowned medtech regulatory expert in an interview with Medtech Insight.

More from Medtech Insight

Tariffs In Focus: Projections From 4 Medtech Giants (Q1 Vs Q2)

 
• By Marion Webb, Shubham Singh, and Nancy Pham

Roche Diagnostics, Intuitive Surgical, Abbott and Edwards Lifesciences all acknowledge tariff headwinds, but stress preparedness, resilience and mitigation. Below is look at how management framed the impact in Q1 vs Q2 earnings calls.

Medtech Must Address AI Risks Now Or Jeopardize Its Future Potential, Expert Warns

 
• By Amanda Maxwell

Urgent action is needed to address gaps in how risks from medical devices and diagnostics utilizing AI are identified, mitigated and managed. So says James Pink, renowned medtech regulatory expert in an interview with Medtech Insight.

Exercise Caution While Using Hyperbaric Oxygen Therapy Devices, FDA Warns

 
• By Brian Bossetta

The US FDA has published a list of recommendations for the safe use of hyperbaric oxygen therapy devices. While the therapy can be effective in treating several conditions, the agency says providers need to understand its potential risks.